PHILADELPHIA – Non-small cell lung cancer patients who had PD-L1 expression in at least half of their tumor cells saw their tumors shrink in greater numbers and lived longer after treatment with Merck's Keytruda (pembrolizumab) than patients with lower levels of expression, researchers reported yesterday at the American Association for Cancer Research annual meeting.
Get the full story with
Premium Access
Only $95 for the
first 90 days*
Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try Premium Access now.
You may already have institutional access!
Check if I qualify.
Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.